Mike Ouimette Sells 13,270 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 13,270 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $148,624.00. Following the transaction, the general counsel now directly owns 80,774 shares of the company’s stock, valued at approximately $904,668.80. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mike Ouimette also recently made the following trade(s):

• On Wednesday, January 22nd, Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock. The shares were sold at an average price of $10.99, for a total value of $112,427.70.

Pliant Therapeutics Stock Up 2.0 %

Pliant Therapeutics stock opened at $11.14 on Friday. The firm has a market cap of $677.87 million, a price-to-earnings ratio of -3.34 and a beta of 1.05. Pliant Therapeutics, Inc. has a 12 month low of $10.22 and a 12 month high of $18.92. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $13.18 and a two-hundred day simple moving average of $13.06.

Pliant Therapeutics (NASDAQ:PLRX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.04. Equities analysts predict that Pliant Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $40.50.

Hedge Funds Weigh In On Pliant Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PLRX. R Squared Ltd purchased a new position in shares of Pliant Therapeutics in the 4th quarter worth $33,000. Atria Investments Inc purchased a new position in shares of Pliant Therapeutics in the 3rd quarter worth $112,000. Deerfield Management Company L.P. Series C purchased a new position in Pliant Therapeutics during the second quarter valued at $126,000. China Universal Asset Management Co. Ltd. lifted its position in Pliant Therapeutics by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in Pliant Therapeutics during the third quarter valued at $145,000. 97.30% of the stock is currently owned by hedge funds and other institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.